Your browser does not support JavaScript capabilities, which maybe required to display this page properly.


PDF FormatRequires Adobe Acrobat Reader

Table 7.6a

Immunosuppression Use for Induction, 1999 to 2008

Recipients with Pancreas After Kidney (PAK) Transplants

  Year of Transplant
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Transplants 220 305 305 375 344 420 343 293 261 214
With Immunosuppression Info 217 299 303 372 336 409 337 283 249 206
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 8.3% 1.7% 0.3% 2.4% 0.6% 1.5% 3.3% 0.0% 1.2% 1.0%
OKT3 8.8% 3.0% 0.7% 1.3% 0.9% 0.2% 0.0% 0.7% 0.4% 1.0%
Thymoglobulin 30.0% 37.1% 50.5% 51.9% 50.9% 57.2% 53.7% 56.2% 61.4% 51.9%
Zenapax 36.9% 32.4% 33.3% 25.3% 9.5% 6.6% 6.8% 2.5% 2.0% 4.4%
Simulect 10.6% 17.1% 13.2% 8.3% 8.0% 5.4% 2.7% 6.7% 4.0% 8.3%
Campath 0.0% 0.0% 0.0% 0.0% 13.4% 19.1% 18.4% 13.4% 12.0% 15.0%
No Induction Drugs Recorded 33.6% 33.4% 25.1% 27.2% 25.9% 20.3% 22.0% 21.9% 20.5% 20.4%


Source: OPTN/SRTR Data as of May 4, 2009.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.



PDF FormatRequires Adobe Acrobat Reader